Publications:
Our Research

Immunogenicity of a fourth Homologous dose of NVX-CoV2373

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study

With established safe and effective use, protein vaccines offer another choice against COVID-19

Safety and immunogenicity of a booster dose of Novavax COVID-19 vaccine, Adjuvanted (NVX-CoV2373) in adults from the PREVENT-19 trial in the United States

Update on NovavaxInvestigational Influenza vaccine and COVID-19-Influenza Combination Vaccine development

Paving the way for protein: Novavax’s COVID-19 vaccine as a booster and variant-adapted

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates